Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Globe Newswire•10/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $21.6 million, up 65% year-over-year
- ➤Full-year 2026 revenue guidance raised to $78 million-$80 million
- ➤Q3 net loss widened to $12.2 million from $8.5 million
- ➤Aprevo lumbar procedures gained increased inpatient CMS reimbursement
- ➤Aprevo Lumbar Bi-lateral Posterior System launched targeting approximately 30,000 annual U.S. procedures
Expert Statements
Mike Cordonnier, Chairman and CEO of Carlsmed
“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year”
Mike Cordonnier, Chairman and CEO of Carlsmed
“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”
Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year
Full year 2026 revenue guidance raised to $78 million to $80 million
Get started
Create a free account to read the full story.